title: Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%.
abstract: The purpose of this study was to assess the safety and efficacy of ipratropium bromide nasal spray 0.06% (aqueous solution), 84 micrograms per nostril three times a day, in reducing nasal hypersecretion in the long-term treatment of patients with perennial allergic rhinitis (PAR). This was an open-label 1-year trial. In the first 6 months all patients were treated with two puffs ipratropium bromide nasal spray 0.06%, 84 micrograms per nostril three times per day, unless they were unable to tolerate the dose. In the last 6 months the dose could be reduced to the lowest amount required to control rhinorrhea. Ninety-six patients entered the trial, and 47 completed it. Sixty-three patients completed more than 6 months of treatment. Patient and physician global evaluation suggested that ipratropium bromide nasal spray 0.06% is effective in controlling rhinorrhea associated with PAR and can contribute to control of congestion, postnasal drip, and sneezing. There was also a trend toward reduction of mucosal edema and improvement in quality of life. The most common drug-related adverse events were nasal dryness, epistaxis/nose bleed, and increased rhinitis. Most adverse events were mild and resulted in drug discontinuation in less than 10% of patients. Ipratropium bromide nasal spray was well tolerated and not associated with serious drug-related adverse events or clinically significant anticholinergic side effects. Use of ipratropium bromide nasal spray alone or with other standard medications should be considered in treating patients with PAR.
authors.affiliation: University of Minnesota, Minneapolis 55402, USA.
authors.forename: H B
authors.initials: HB
authors.lastname: Kaiser
authors.forename: S R
authors.initials: SR
authors.lastname: Findlay
authors.forename: J W
authors.initials: JW
authors.lastname: Georgitis
authors.forename: J
authors.initials: J
authors.lastname: Grossman
authors.forename: P H
authors.initials: PH
authors.lastname: Ratner
authors.forename: D G
authors.initials: DG
authors.lastname: Tinkelman
authors.forename: P
authors.initials: P
authors.lastname: Roszko
authors.forename: E
authors.initials: E
authors.lastname: Zegarelli
authors.forename: C C
authors.initials: CC
authors.lastname: Wood
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000187:drug effects / Q000378:metabolism; D009330:Nebulizers and Vaporizers; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
chemical_list: D009241:Ipratropium